Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome


Creative Commons License

Ocuz A. , Uzunlulu M.

INTERNATIONAL HEART JOURNAL, cilt.49, ss.303-311, 2008 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 49 Konu: 3
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1536/ihj.49.303
  • Dergi Adı: INTERNATIONAL HEART JOURNAL
  • Sayfa Sayısı: ss.303-311

Özet

Elevated concentrations of asymmetric dimethylarginine (ADMA), all endogeneous inhibitor of nitric oxide synthase, are associated with endothelial dysfunction. Metabolic syndrome (MetS) is also a condition associated with impaired endothelial function. To test the hypothesis that lipid lowering treatment with a statin lowers ADMA levels, we investigated file effect of fluvastatin treatment on serum ADMA levels in patients with MetS.